Tags

Type your tag names separated by a space and hit enter

Abaloparatide for the treatment of postmenopausal osteoporosis.
Drugs Today (Barc). 2018 May; 54(5):293-303.DT

Abstract

Abaloparatide is a synthetic 34-amino acid peptide analogue of the 1-34 portion of the human parathyroid hormone-related protein (PTHrP). It has been approved in the U.S. for the treatment of postmenopausal women with osteoporosis at a high risk for fracture. Abaloparatide is an anabolic agent and it seems to have a potent anabolic activity with reduced effects on bone resorption. It reduces the risk of vertebral and nonvertebral fractures, major osteoporotic fractures and clinical fractures, with a significant improvement in bone mineral density at femoral neck, total hip and lumbar spine. In this article we summarize the development of the abaloparatide molecule and preclinical and clinical studies published so far. Results from clinical trials indicate that abaloparatide may become an important option for the anabolic treatment of postmenopausal osteoporosis.

Authors+Show Affiliations

University of Milan, Health Sciences Department, Milan, Italy. luca.pietrogrande@unimi.it.Azienda Socio Sanitaria Territoriale Santi Paolo e Carlo, Unità Operativa di Ortopedia e Traumatologia, Milan, Italy.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

29911694

Citation

Pietrogrande, L, and E Raimondo. "Abaloparatide for the Treatment of Postmenopausal Osteoporosis." Drugs of Today (Barcelona, Spain : 1998), vol. 54, no. 5, 2018, pp. 293-303.
Pietrogrande L, Raimondo E. Abaloparatide for the treatment of postmenopausal osteoporosis. Drugs Today (Barc). 2018;54(5):293-303.
Pietrogrande, L., & Raimondo, E. (2018). Abaloparatide for the treatment of postmenopausal osteoporosis. Drugs of Today (Barcelona, Spain : 1998), 54(5), 293-303. https://doi.org/10.1358/dot.2018.54.5.2800621
Pietrogrande L, Raimondo E. Abaloparatide for the Treatment of Postmenopausal Osteoporosis. Drugs Today (Barc). 2018;54(5):293-303. PubMed PMID: 29911694.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Abaloparatide for the treatment of postmenopausal osteoporosis. AU - Pietrogrande,L, AU - Raimondo,E, PY - 2018/6/19/entrez PY - 2018/6/19/pubmed PY - 2018/8/24/medline KW - Abaloparatide KW - Bone disorders KW - Parathyroid hormonerelated protein (PTHrP) KW - Postmenopausal osteoporosis SP - 293 EP - 303 JF - Drugs of today (Barcelona, Spain : 1998) JO - Drugs Today (Barc) VL - 54 IS - 5 N2 - Abaloparatide is a synthetic 34-amino acid peptide analogue of the 1-34 portion of the human parathyroid hormone-related protein (PTHrP). It has been approved in the U.S. for the treatment of postmenopausal women with osteoporosis at a high risk for fracture. Abaloparatide is an anabolic agent and it seems to have a potent anabolic activity with reduced effects on bone resorption. It reduces the risk of vertebral and nonvertebral fractures, major osteoporotic fractures and clinical fractures, with a significant improvement in bone mineral density at femoral neck, total hip and lumbar spine. In this article we summarize the development of the abaloparatide molecule and preclinical and clinical studies published so far. Results from clinical trials indicate that abaloparatide may become an important option for the anabolic treatment of postmenopausal osteoporosis. SN - 1699-3993 UR - https://www.unboundmedicine.com/medline/citation/29911694/Abaloparatide_for_the_treatment_of_postmenopausal_osteoporosis_ L2 - http://journals.prous.com/journals/servlet/xmlxsl/pk_journals.xml_summaryn_pr?p_JournalId=4&p_RefId=2800621 DB - PRIME DP - Unbound Medicine ER -